Launch of the first US generic of Amgen Inc.’s hyperparathyroidism treatment Sensipar (cinacalcet) moved two steps closer to reality with a federal judge’s patent noninfringement ruling for Piramal Healthcare UK Ltd., followed just days later by FDA approval of the company’s abbreviated new drug application (ANDA).
The two events position Piramal as the only cincalcet ANDA sponsor with full approval and a court ruling of noninfringement...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?